Amylyx moved closer to a potential filing milestone by banking $500 million ahead of submission, according to a finance report. The update positions the company to fund late-stage and regulatory-facing activities while managing runway risk. Sector read-through: as clinical readouts tighten the timeline to submissions, investors are increasingly rewarding financing plans that reduce dependence on near-term capital markets during regulatory review.